Nuwellis, Inc. (NUWE) NASDAQ
0.59
-0.1091(-15.58%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.59
-0.1091(-15.58%)
Currency In USD
| Previous Close | 0.7 |
| Open | 0.7 |
| Day High | 0.71 |
| Day Low | 0.57 |
| 52-Week High | 34.02 |
| 52-Week Low | 0.54 |
| Volume | 334,113 |
| Average Volume | 88,777 |
| Market Cap | 533,475 |
| PE | -0.02 |
| EPS | -26.89 |
| Moving Average 50 Days | 1.06 |
| Moving Average 200 Days | 2.42 |
| Change | -0.11 |
Nuwellis Appoints Dr. Stuart L. Goldstein as Director of Clinical Strategy to Advance Pediatric and Cardiorenal Strategy
GlobeNewswire Inc.
Mar 05, 2026 1:00 PM GMT
Appointment Strengthens Clinical Leadership in Precision Fluid Management and Acute Kidney InjuryMINNEAPOLIS, March 05, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patie
Nuwellis Appoints David A. McDonald and Martin J. Emerson to Board of Directors
GlobeNewswire Inc.
Feb 26, 2026 1:00 PM GMT
MINNEAPOLIS, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced the appointment of David A. McDonald and Martin J
Nuwellis, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026
GlobeNewswire Inc.
Feb 24, 2026 1:00 PM GMT
MINNEAPOLIS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it will release financial results for the fo